UP!

DCTH $10.86   View long term graphs

Delcath Systems
Formation 1988
Purpose specialty pharmaceutical
Headquarters Delaware
Services Pharmaceutical and medical device company focused on oncology
Website http://delcath.com/

Delcath Systems, Inc. Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly-traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-11-12 Future report Set alerts
Q2 2020 2020-08-06 0.00 0.00
Q1 2020 2020-05-15 0.00 -108.07
Q4 2019 2020-03-25 0.00 -225.04
Q3 2019 2019-11-14 0.00 -805.71
Q2 2019 2019-08-08 0.00 -45.71
Q1 2019 2019-07-14 0.00 -62.86
Q4 2018 2019-06-14 0.00 -234.29
Q3 2018 2018-11-13 0.00 -142.86
Q2 2018 2018-08-14 0.00 -4.00

Ratings

9659-03-21
9604-03-07
6752-03-19
3889-03-31
2486-03-09
2010-06-08 Initiated BioLogic Equity Research Sell
2010-04-22 Reiterated Wedbush Outperform $7.50 to $21
2009-11-30 Initiated Wedbush Morgan Outperform
2008-06-10 Initiated Canaccord Adams Buy $2.65
1970-01-01
9659-03-21
9604-03-07
6752-03-19
3889-03-31
2486-03-09

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Taglietti Marco 2.33%  (220000) DCTH / FRX / NRX / SCYX /
Taney Richard 2.24%  (211485) DCTH /
Philips Laura A 2.17%  (205299) DCTH /
HOBBS EAMONN P President and CEO 1.71%  (162000) ATRS / DCTH / OSUR /
Kandarpa Krishna Exec. V.P., Chief Medical Off. 1.68%  (159000) DCTH /
WATSON DOUGLAS G 1.45%  (136664) DCTH / DNDN / OSUR / WMGI /
STOLL ROGER G PHD 1.05%  (99145) CHTP / DCTH /
GAGO AGUSTIN V EVP Global Sales & Marketing 0.86%  (80944) DCTH /
LADD ROBERT 0.74%  (69534) DCTH / MGT /
Miao Graham G Exec. V.P., CFO 0.57%  (54000) DCTH / PDII / PTX /
McDonald David Chief Financial Officer 0.50%  (47706) DCTH /
Koplewicz Harold S 0.48%  (45052) DCTH /
Simpson Jennifer K. Exec. VP, Global Marketing 0.44%  (41908) DCTH /
Rueckert William Dodge 0.42%  (40000) CHTP / DCTH / MEIP /
Purpura John EVP Reg. Affairs/Quality Assur 0.37%  (35398) DCTH /
Keck Barbra Vice President, Controller 0.25%  (23887) DCTH /
LEUNG GABRIEL 0.23%  (21485) AMRI / DCTH / PTX /
LANGER DENNIS 0.21%  (20000) DCTH / DRNA / MYGN / MYRX / PTX /
MAPES HAROLD Exec. V. P., Global Operations 0.18%  (17000) DCTH /
GRAHAM PETER J EVP; General Counsel 0.16%  (15000) ATRS / DCTH /
Brege Laura 0.12%  (11678) ACAD / DCTH / DVAX / PCRX / PETX / PTLA /
Konidaris Tasos 0.12%  (11678) DCTH / KDMN / PTX /
Contag Pamela Reilly 0.09%  (8507) DCTH / MBII /

Comments